NCT05678933 is a Phase 3 clinical trial of Azacitidine in Peripheral T-cell Lymphoma Targeted Therapy, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT05678933?

NCT05678933 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT05678933?

Interventions in NCT05678933: Azacitidine, Chidamide, Cyclophosphamide, Epirubicin, Vincristine, Prednisone.

What condition does NCT05678933 study?

NCT05678933 studies Peripheral T-cell Lymphoma Targeted Therapy.

Is NCT05678933 still recruiting?

NCT05678933 is currently enrolling by invitation. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT05678933

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

ENROLLING BY INVITATION Phase 3 Last updated 10 January 2023

What this trial tests

Phase 3 trial testing Azacitidine in Peripheral T-cell Lymphoma Targeted Therapy in 200 participants. Enrolling by invitation.

Timeline

1 January 2023

Primary endpoint
1 December 2027

1 December 2029

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 3
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	1 January 2023
Primary completion	1 December 2027
Estimated completion	1 December 2029
Sites	1 location across China

Drugs / interventions tested

Azacitidine (azacitidine) — full drug profile →
Chidamide
Cyclophosphamide (cyclophosphamide) — full drug profile →
Epirubicin (EPIRUBICIN) — full drug profile →
Vincristine (vincristine) — full drug profile →
Prednisone (prednisone) — full drug profile →

Conditions studied

Peripheral T-cell Lymphoma Targeted Therapy — all drugs for Peripheral T-cell Lymphoma Targeted Therapy →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 70, any sex, with Peripheral T-cell Lymphoma Targeted Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to receive either (arm A) azacitidine administered IH at day 1-5 and chidamide admistered twice a week for two weeks in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or (arm B) CHOP administered every 3 weeks for 6 cycles in patients with previously untreated peripheral T-cell lymphoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.
Song J, Yang P, Chen C, Ding W, et al · · 2025 · cited 40× · PMID 40675967 · DOI 10.1038/s41392-025-02266-z
BV and beyond: how to incorporate novel agents into PTCL management.
Nizamuddin IA, Mehta-Shah N. · · 2024 · cited 2× · PMID 39644004 · DOI 10.1182/hematology.2024000530

Verify or expand the search:

Other trials of Azacitidine

Trials testing the same drug.

NCT07508982 — Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML · Phase 1, PHASE2 · not yet recruiting
NCT05554419 — Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Tr · Phase 2 · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
NCT07469046 — VAH vs VA in Newly Diagnosed Elderly AML · Phase 3 · not yet recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05678933 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05678933.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing